Pharmacological and / or genetic activator for use in preserving and regenerating muscle structure and function by blocking senescence
Activating the TSHR signaling pathway in muscle stem cells addresses the issue of cellular senescence in Duchenne muscular dystrophy, enhancing muscle regeneration and slowing disease progression.
Patent Information
- Application Number
- FR2021008489
- Authority / Receiving Office
- FR · FR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-08-04
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current therapies for Duchenne muscular dystrophy do not effectively target cellular senescence of muscle stem cells, leading to reduced muscle regeneration and worsening of the pathology.
A pharmacological and/or genetic activator of the thyroid-stimulating hormone receptor (TSHR) signaling pathway is used to preserve and regenerate muscle structure and function by blocking senescence in muscle stem cells.
This approach increases muscle regeneration, prevents muscle wasting, and maintains muscle functionality by blocking senescence, thereby slowing the progression of Duchenne muscular dystrophy.
Smart Images

Figure 00000033_0000 
Figure 00000034_0000 
Figure 00000034_0001
Abstract
Description
Title of the invention: Pharmacological and / or genetic activator for use in preserving and regenerating muscle structure and function by blocking senescence Technical field
[0001] The invention relates to a novel pharmacological and / or genetic activator for use in preserving and regenerating muscle structure and function by blocking senescence, in particular for preventing and / or treating myopathies, preferably Duchenne muscular dystrophy (DMD), as well as sarcopenia. The invention also relates to a novel adenoviral vector for use as a medicament. Prior art
[0002] Muscular dystrophy is a hereditary neuromuscular disorder of a progressive nature, resulting from the mutation of one or more genes intended to ensure muscular functions and structures.
[0003] Duchenne muscular dystrophy is the most common childhood myopathy. It is caused by abnormalities in a protein essential to muscles, dystrophin. It is characterized by a decline in muscle regeneration, contributing to the loss of muscle mass.
[0004] In patients with Duchenne muscular dystrophy, in the absence of dystrophin, the fibers that make up skeletal muscles, smooth muscles and cardiac muscle are damaged with each contraction and eventually destroyed.
[0005] Duchenne muscular dystrophy is caused by a recessive genetic abnormality in the DMD gene on the X chromosome, resulting in the absence of dystrophin.
[0006] Dystrophin is a large protein that provides the link between the contractile cytoskeleton and the extracellular matrix, through a protein complex called the dystrophin membrane complex, and plays a major role in maintaining the integrity of muscle fibers during contraction.
[0007] Dystrophin is a protein consisting of 3685 amino acids with a molecular weight of 427 kDa. It is encoded by the DMD gene, which allows the synthesis of 7 main isoforms of different sizes, thanks to the presence of 7 tissue-specific promoters.
[0008] Three of these promoters (called M, B and P promoters indicating expression in the tissues “Muscle”, “Brain” and “Purkinje neurons of the cerebellar cortex” ) are located upstream of the first exon and allow the synthesis of functionally full-length dystrophins equivalent.
[0009] The other four promoters are intragenic and allow the synthesis of reduced size isoforms.
[0010] Dystrophin is part of the family of filamentous proteins of the "spectrin" type which are present in skeletal and cardiac muscle tissues, the brain, the retina, glial and Purkinje cells and in very reduced quantities in lymphocytes.
[0011] Dystrophin is composed of four major domains that interact with several partners of the muscle cell and play an essential role during the muscle contraction-relaxation cycle: - the N-terminal domain or actin binding domain (ABD1), comprising the first 246 amino acids; - the central domain (or rod domain) ranging from amino acid 247 to 3045. It is made up of 24 repeats homologous to spectrin (or spectrin like, RI to R24) and 4 proline-rich hinges (or hinges, H1 to H4) dividing the central domain into 3 subdomains; - the cysteine-rich repeats (CR) domain ranging from amino acid 3080 to 3360; and - the C-terminal domain formed by the last 325 residues.
[0012] Numerous clinical trials are underway for the treatment of Duchenne muscular dystrophy using gene or pharmacological therapy.
[0013] Gene therapies aim to obtain functional dystrophin production in the muscle.
[0014] A first clinical trial recently began in France. It is evaluating a gene therapy product combining a shortened version of the DMD gene and an adeno-associated viral vector (AAV).
[0015] Pharmacological therapies act on certain manifestations of the disease to slow its progression. Several drugs are being studied to improve and / or protect muscle and / or cardiac function, combat inflammation and the effects of the absence of dystrophin on muscle cells: tamoxifen, nebivolol, givinostat, rimeporide, etc.
[0016] Patent document WO2018155913 relates to a composition comprising chemical compounds selected from pan-histone deacetylase inhibitors, ALK5 inhibitors (activin A receptor-like kinase 5 inhibitor) and cAMP signaling activators for inducing the differentiation of somatic cells, mesenchymal stem cells or adult stem cells (except muscle stem cells) into skeletal muscle cells for the treatment of skeletal muscle diseases. It implements a A method in which cells are cultured in a culture medium containing the composition inducing differentiation into skeletal muscle cells. The skeletal muscle cells thus obtained do not present any risk of oncogenesis after implantation due to differentiation from somatic cells, and have the advantage of being genetically stable due to the use of a mixture of low molecular weight compounds alone, without the introduction of genetics. Technical problem
[0017] Considering the above, a problem which the present invention proposes to solve consists in developing a new therapy for preserving and regenerating muscle structure and function and in particular treating Duchenne muscular dystrophy.
[0018] However, to date, no known therapy aims to target the cellular senescence of muscle stem cells to treat Duchenne muscular dystrophy. Muscle stem cell senescence is one of the effects caused by Duchenne muscular dystrophy (Sugihara, Hidetoshi et al. “Cellular senescence-mediated exacerbation of Duchenne muscular dystrophy.” Scientific reports vol. 10,1 16385. 12 Oct. 2020, doi:10.1038 / s41598-020-73315-6). This contributes to the severe reduction in muscle regeneration and thus causes the pathology to worsen. Solution provided
[0019] The solution to this problem posed has as its first object a pharmacological and / or genetic activator of the thyroid-stimulating hormone receptor (TSHR) signaling pathway in muscle stem cells (satellite cells) for its use in preserving and regenerating muscle structure and function by blocking senescence.
[0020] Surprisingly, targeting TSHR signaling pharmacologically and / or genetically allows preserving the proliferation and differentiation capacities of muscle stem cells by blocking senescence. Activation of TSHR signaling in muscle stem cells increases the regenerative properties of muscles affected in particular by Duchenne muscular dystrophy and preserves muscle structure and function, preventing the rapid muscle wasting that occurs with the progression of the pathology.
[0021] It also relates to a combination of a pharmacological activator and a genetic activator for their uses according to the invention.
[0022] The invention also relates to an adenoviral vector characterized in that it comprises a protein sequence of the thyroid-stimulating hormone receptor (TSHR) of SEQ ID NO: 1 or a functional variant having a protein sequence at least 60% identical to the sequence SEQ ID NO: 1, or a nucleotide sequence of the TSHR of SEQ ID NO: 2 or a functional variant having a nucleotide sequence at least 60% identical to the sequence SEQ ID NO: 2 for use as a medicament. Advantages provided
[0023] The Applicant has in particular been able to develop a pharmacological and / or genetic activator of the thyroid-stimulating hormone receptor (TSHR) signaling pathway in muscle stem cells, making it possible to increase muscle regeneration by preventing the loss of muscle mass and substitution by adipose and fibrous tissues. This approach will make it possible to maintain muscle functionality and slow the progression of Duchenne muscular dystrophy. Brief description of the drawings
[0024] The invention and the advantages resulting therefrom will be better understood upon reading the description and the non-limiting embodiments which follow, illustrated with reference to the appended drawings in which: Fig.l
[0025] [Fig.l] illustrates the generation of R-DMDdel52 rats as detailed in Example 1 in which: IA) is an observation of Dystrophin and [3-Dystroglycan (in gray) by immunofluorescence in the anterior tibia of WT rats and R-DMDdel52 rats at 3 weeks and 12 months of age. (Scale bar = 20 pm). IB) is an analysis of the expression level of Dystrophin in the foretibia of a WT rat and two R-DMDdel52 rats (DMD #1, DMD#2) at 16 weeks of age by Western Blot. [3-Tubulin is used as a housekeeping gene. IC) represents a survival curve of WT rats and DMD rats by the Kaplan Meier estimator. ID) details the staining of anterior tibial muscle tissue, with Hematoxylin and Eosin (top panel) and Sinus Red (bottom panel), from WT and R-DMDdel52 rats at 12 months of age. (Scale bar = 20 pm). 1E) represents the quantification of fibrous tissue deposition using the percentage of Sirius red-stained surface area at the anterior tibia in WT and R-DMDdel52 rats aged 12 months. Mean ± standard deviation (n=3), Mann-Whitney test. 1F) corresponds to the percentage of centrally nucleated myofibrils in the anterior tibia of WT and R-DMDdel52 rats at 12 months of age. Mean ± SD (n=3), Mann-Whitney test. IG) corresponds to the percentage distribution of muscle fiber sizes in the cross-section at the anterior tibia in WT and R-DMDdel52 rats at 12 months of age. Mean ± standard deviation (n=3), ANOVA test. P values are calculated by Sidak's post test. 1H) details the staining of extraocular muscles, with Hematoxylin and Eosin (top panel, white) and Sinus Red (bottom panel, black), from WT and R-DMDdel52 rats at 12 months of age. (Scale bar = 20 pm). II) represents the quantification of fibrous tissue deposition using the percentage of Sirius red-stained surface area in the extraocular muscles of WT and R-DMDdel52 rats aged 12 months. Mean ± standard deviation (n=3), Mann-Whitney test. IJ) corresponds to the percentage of centrally located myofibrils in the extraocular muscles of WT and R-DMDdel52 rats at 12 months of age. Mean ± standard deviation (n=3), Mann-Whitney test. IP) corresponds to the percentage distribution of the cross-sectional area at the level of the extraocular muscles in WT and R-DMDdel52 rats at 12 months of age. Mean ± standard deviation (n=3), ANOVA test. P values are calculated by Sidak's post test. Fig.2
[0026] [Fig.2] illustrates the continuous muscle regeneration of the extraocular muscles pro progressive in the rat DMD model as detailed in Example 2 in which: 2A) is an observation of embryonic myosin heavy chain (eMHC, gray cluster in the lower left panel) and laminin (in the form of a network) in the anterior tibia of WT and R-DMDdel52 rats aged 3 weeks, 6 months and 12 months, by immunofluorescence, the nucleus is labeled with Hoechst blue dye. (Scale bar = 20 pm). 2B) corresponds to the quantifications of the number of eMHC per mm2 at the level of the anterior tibia of WT and R-DMDdel52 rats aged 3 weeks, 6 months and 12 months. Mean ± standard deviation (n=3), Mann-Whitney test. 2C) is an observation of the eMHC light chain (grey cluster) and laminin (in the form of a condensed network) in the extraocular muscles of WT and R-DMDdel52 rats aged 3 weeks, 6 months and 12 months, by immunofluorescence, the nucleus is labeled with Hoechst blue dye. (Scale bar = 20 pm). 2D) corresponds to the quantifications of the number of eMHC per mm2 in the extraocular muscles of WT and R-DMDdel52 rats aged 3 weeks, 6 months and 12 months. Mean ± standard deviation (n=3), Mann-Whitney test. 2E) is a representative co-immunofluorescence staining in the anterior tibia using Ki67 (in white triangle), Pax7 (box 0), laminin (in lattice form) and Hoechst (circles in cells) antibodies. Yellow boxes indicate co-expression of Pax7 and Ki67 and gray rectangles indicate PAX7+ / Ki67- muscle stem cells. (Scale bar = 10 pm). 2F) represents the quantification of E showing the number of muscle cells (PAX7+) per fiber at the anterior tibia of WT and R-DMDdel52 rats aged 3 weeks, 6 months and 12 months. Mean ± standard deviation (n=3), Mann-Whitney test. 2G) represents the quantification of the percentage of quiescent (Pax7+ / Ki67-) and proliferative (Pax7+ / Ki67+) MSCs on the TAs isolated from WT and R-DMDdel52 rats aged 3 weeks, 6 months and 12 months. Mean ± standard deviation (n=3), Mann-Whitney test. Fig.3
[0027] [Fig.3] illustrates the myogenic potential of MSCs from R-DMDdel52 rats of the TA in vitro in which: 3A-B) correspond to representative co-immunofluorescence staining of Ki67 (circle), MyoD (square) and nuclei (Hoechst, star) of myoblasts isolated from the anterior tibia (A) and extraocular muscles (B) of 3-week-old WT and R-DMDdel52 rats. Arrows indicate proliferative myoblasts co-labeled with Ki67 and MyoD. Scale bar 20 μm. 3C) corresponds to the quantifications of MyoD+ / Ki67+ and MyoD+ / Ki67- myoblasts from the anterior tibia and extraocular muscles of 3-week-old WT and R-DMDdel52 rats. Mean ± SD (n=3), Mann-Whitney test. 3D-E) represent the immunofluorescence labeling of sarcomeric myosins (MF20 in filament form) and nuclei (Hoechst,) of differentiated myotubes in the anterior tibia (D) and extraocular muscles (E) of 3-week-old WT and R-DMDdel52 rats. Scale bar 20 pm. 3F) is an assessment of the fusion index per field on differentiated myotubes of the and MEO (Extra-Ocular Muscles) at 3 weeks of age. Means ± standard deviation (n = 3), Mann-Whitney test. 3G) represents the number of nuclei per myotube per field (mm2) for WT and R-DMDdel52 myotubes isolated from TA and MEO at 3 weeks of age. Means ± SD (n = 3), Mann-Whitney test. HI) correspond to co-immunofluorescence staining of Ki67, MyoD and nuclei (Hoechst) of myoblasts isolated from the TA (H) and MEO (I) of 6-month-old WT and R-DMDdel52 rats. Arrows indicate proliferative myoblasts co-labeled with Ki67 and MyoD, while stars highlight MyoD+ / Ki67- myoblasts. Scale bar 20 pm. 3J) represents the quantifications of MyoD+ / Ki67+ and MyoD+ / Ki67- myoblasts from TA and WT and R-DMDdel52 MEO at 6 months. Means ± standard deviation (n = 3), Mann-Whitney test. 3K-L) correspond to immunofluorescence staining of sarcomeric myosins (MF20, green) and nuclei (Hoechst, blue) of differentiated myotubes of the TA (K) and MEOs (L) from 6-month-old WT and R-DMDdel52 rats. Scale bar 20 [im. 3M) is an assessment of the fusion index per field on differentiated myotubes of the TA and MEO of 6-month-old rats. Means ± standard deviation (n = 3), Mann-Whitney test. 3N) represents the number of nuclei per myotube per field (mm2) for WT and R-DMDdel52 myotubes isolated from the TA and MEO of 6-month-old rats. Means ± SD (n = 3), Mann-Whitney test. 30) corresponds to co-immunofluorescence staining of EdU, Pax7 / MyoD and nuclei (Hoechst) of FACS-sorted myoblasts from isolated limb muscles of 6-month-old WT and R-DMDdel52 rats. Arrows indicate proliferative myoblasts co-labeled with Ki67 and MyoD, while stars highlight MyoD-positive myoblasts negative for Ki67. Scale bar 20qm. 3P) corresponds to the percentage of cell type (Pax7+ / MyoD+ and Pax7+ / MyoD-) to assess cell purity after FACS sorting. 3Q) is the quantification of proliferative (EdU+) (Pax7:MyoD+) myoblasts from FACS-sorted cells isolated from limb muscles of 6-month-old WT and R-DMDdel52 rats. Means ± SD (n = 3), Mann-Whitney test. 3R) is immunofluorescence staining of sarcomeric myosins (MF20, as a broad band (WT) and a thick line (DMD)) and nuclei (Hoechst, circle) on myotubes differentiated from FACS-sorted myoblasts of 6-month-old WT and R-DMDdel52 rats. Scale bar 50qm. 3S) corresponds to the quantification of the fusion index per field for the experiment carried out in (R). Fig.4
[0028] [Fig.4] illustrates the expression of senescence markers at the level of sa cells Tibialis anterior (TA) muscle tellites R-DMDdel52 as detailed in Example 4, wherein:.
[0029] 4A) corresponds to a graph drawn by the t-SNE algorithm on the grouping of muscle-resident cell populations, revealed by scRNA-seq analysis on TA of 12-month-old WT and R-DMDdel52 rats. 4B) corresponds to a t-SNE plot split between WT and R-DMDdel52. 4C) corresponds to a t-SNE plot showing the expression of Cdkn1a and Cdkn2a in muscle stem cells (MSCs) from WT and R-DMDdel52 samples. 4D) represents violin plots showing the gene expression distribution of Pax7 and Myf5 as CSM-specific genes and Cdknla and Cdkn2a as senescence markers. 4E-FG) correspond to co-immunofluorescence staining of TA, using antibodies against Pax7, Cdkn2a (also called p16; star, E) or Cdkn1a (also called p21; star, F) or yH2AX (star, G), laminin (in lattice form) and Hoechst for nuclei. Triangles highlight PAX7+ MSCs. Scale bar 10pm. 4H) corresponds to the quantification of E showing the percentage of CSM (Pax7+) co-expressing Cdkn2a at 3 weeks, 6 months and 12 months at the TA level of WT and R-DMDdel52 rats. Means ± standard deviation (n = 3), Mann-Whitney test. 41) corresponds to the quantification of F showing the percentage of CSM (Pax7+) co-expressing Cdknla at 3 weeks, 6 months and 12 months at the TA level in WT and R-DMDdel52 rats. Means ± standard deviation (n = 3), Mann-Whitney test. 4J) corresponds to the quantification of G showing the percentage of CSM (Pax7+) co-expressing yH2AX at the age of 3 weeks, 6 months and 12 months at the TA level of WT and R-DMDdel52 rats. Means ± standard deviation (n = 3), Mann-Whitney test. Fig.5
[0030] [Fig.5] illustrates the expression of senescence markers at the level of MSCs of human patients with DMD as detailed in Example 5, wherein: 5A) represents immunofluorescence for embryonic myosin heavy chain (eMHC, large filled gray circle) and laminin (as an array) on control and DMD human biopsies at age 1-2, 3-4, 5-6, 7-8 years. Scale bar 20qm. 5B) corresponds to the quantification of the number of eMHC+ myofibers per mm2 compared to A. Means ± standard deviation (Control n=12; DMD n=20), Mann-Whitney test. 5C) is a co-immunofluorescence staining of DMD and control muscle biopsies, using antibodies against Pax7, Cdkn2a (red), and Hoechst. Yellow triangles highlight PAX7+ MSCs. Scale bar 10 μm. 5D) represents the quantification of C showing the percentage of Pax7 MSCs co-expressing Cdkn2a in DMD and control muscle biopsies. Means ± standard deviation (Control n=12; DMD n=20), Mann-Whitney test. 5E) represents a Pearson correlation test showing the correlation between DMD MSCs expressing Cdkn2a and age (Control n=12; DMD n=20). 5F) is a representative co-immunofluorescence staining of DMD and control muscle biopsies using antibodies against Pax7, yH2AX (star), and Hoechst. Triangles highlight PAX7+ MSCs. Scale bar 10 μm. 5G) represents the quantification of F showing the percentage of MSCs (Pax7+) co-expressing yH2AX in DMD and control muscle biopsies. Means ± standard deviation (Control n=12; DMD n= 15), Mann-Whitney test. 5H) represents a Pearson correlation test between DMD MSCs expressing yH2AX and age (Control n=12; DMD n=15). Fig.6
[0031] [Fig.6] illustrates the expression of a specific signature of CSMs at the level of MEOs distinct from that at the TA as detailed in Example 6, wherein: 6A) is a t-SNE plot of the clustering of muscle-resident cell populations revealed by scRNA-seq at the TA (left panels) and MEOs (right panels) of 12-month-old WT and R-DMDdel52 rats, showing the expression of Pax7, Pitx2, Cdkn1a, Cdkn2a, and Tshr. The squares indicate the MSC cluster. 6B-C) represent Violin plots showing the gene expression distribution of Pax7, Cdknla, Cdkn2a in B and Myf5, Pitx2 and Tshr in C from scRNAseq analysis performed in the TA and MEO of 12-month-old WT and R-DMDdel52 rats. 6D) is a qPCR analysis of MEO- and limb-derived myoblasts as expression fold change relative to MEO-derived myoblasts for Cdkn1a, Cdkn2a, and Tshr. Means ± SD (n = 3), Mann-Whitney test. 6E-G) correspond to co-immunofluorescence staining of MEOs, using antibodies against Pax7, Cdkn2a (E) or Cdkn1a (F) or yH2AX (, G), laminin (in network form) and Hoechst. Triangles highlight MSCs (PAX7+). Scale bar 100 m. 6H) corresponds to the quantification of E showing the percentage of CSM (Pax7+) co-expressing Cdkn2a at 3 weeks, 6 months and 12 months of age of rats at the level of the WT and R-DMDdel52 TA. Means ± standard deviation (n = 3), Mann-Whitney test. 61) corresponds to the quantification of F showing the percentage of CSM (Pax7+) co-expressing Cdknla at 3 weeks, 6 months and 12 months in WT and R-DMDdel52 TA. Means ± standard deviation (n = 3), Mann-Whitney test. 6J) corresponds to the quantification of G showing the percentage of CSM (Pax7+) co-expressing yH2AX at 3 weeks, 6 months and 12 months in WT and R-DMDdel52 TA. Means ± standard deviation (n = 3), Mann-Whitney test. Fig.7
[0032] [Fig.7] illustrates the regulation of senescence at the level of myoblasts isolated from MEO in R-DMDdel2 rats, in which: 7A) corresponds to immunofluorescence for TSHR (stars) and Pax7 / MyoD on 3-month-old rat myoblasts isolated from MEO (left) and limb muscles (right). Nuclei were stained with Hoechst. Scale bar 20 pm. 7B) is co-immunofluorescence staining of EdU (middle panels), Pax7 / MyoD (left panels), and nuclei (Hoechst, right panels) of OME-derived myoblasts treated with vehicle (DMSO) or ML224. Scale bar 20p,m. 7C) corresponds to the quantifications of proliferative myoblasts (EdU+) (Pax7 / MyoD+) from MEO-derived myoblasts treated with vehicle (DMSO) or the TSHR inhibitor ML224. Means ± standard deviation (n = 3), Mann-Whitney test. 7D) is an immunofluorescence staining of sarcomeric myosins (MF20, as a band) and nuclei (Hoechst) of differentiated myotubes from MEO cells treated with vehicle (DMSO) or ML224. Scale bar 20 μm. 7E) is an assessment of the fusion index per field on differentiated myotubes from MEO, treated with vehicle (DMSO) or ML224. Means ± SD (n = 4), Mann-Whitney test. 7F) corresponds to a qPCR analysis on myoblasts derived from MEO treated with vehicle or ML224, evaluating the gene expression of Cdkn1a and Cdkn2a. Means ± standard deviation (n = 4-5), Mann-Whitney test. 7G) depicts representative co-immunofluorescence staining of Pax7 / MyoD (left panels), EdU (middle panels), and nuclei (Hoechst, right panels) in myoblasts isolated from WT and R-DMDdel52 limb muscles treated with vehicle (DMSO) or the adenylate cyclase activator Forskolin. Scale bar 20qm. 7H) corresponds to the quantifications of Pax7:MyoD+ / EdU+ and Pax7:MyoD+ / EdU- myoblasts from WT and R-DMDdel52 myoblasts isolated from limb muscles after treatment with Forskolin or vehicle (DMSO). Means ± SD (n = 3), Mann-Whitney test. 71-J) correspond to qPCR analysis on vehicle- or Forskolin-treated limb-derived myoblasts from WT and R-DMDdel52 rats, assessing gene expression of Cdkn1a (I) and Cdkn2a (J). Means ± SD (n = 4), Mann-Whitney test. 7K) represents immunofluorescence staining of sarcomeric myosins (MF20, as bands) and nuclei (Hoechst, round) of differentiated myotubes from vehicle (DMSO)- or forskolin-treated WT and R-DMDdel52 limb cells. Scale bar 20qm. 7L) is an assessment of the field fusion index on differentiated myotubes from WT and R-DMDdel52 limb muscles, treated with vehicle (DMSO) or Forskolin. Means ± SD (n = 4), Mann-Whitney test. Description of the embodiments
[0033] The invention relates to a pharmacological and / or genetic activator of the thyroid-stimulating hormone receptor (TSHR) signaling pathway in muscle stem cells (satellite cells) for use in preserving and regenerating muscle structure and function by blocking senescence, preferably in humans and animals, even more preferably in humans.
[0034] Surprisingly, the Applicant was thus able to identify new pharmacological and / or genetic activators of the thyroid-stimulating hormone receptor (TSHR) signaling pathway, taken alone or in combination, for their use specifically at the level of muscle stem cells (satellite cells) to block their senescence.
[0035] TSHR belongs to the rhodopsin family of glycoprotein receptors, which, when activated, stimulates adenylate cyclase, activating the cyclic adenosine monophosphate (cAMP) / protein kinase A (PKA) pathway (Morshed et al., “Characterization of thyrotropin receptor antibody-induced signaling cascades.” Endocrinology vol. 150,1 (2009): 519-29; Rowe et al., “Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.” The New England journal of medicine vol. 377,21 (2017): 2024-2035).
[0036] Muscle stem cell senescence is one of the effects caused by Duchenne muscular dystrophy (DMD). This contributes to the severe reduction in muscle regeneration and thus causes the pathology to worsen.
[0037] Preferably, preserving and regenerating muscle structure and function by blocking the senescence of muscle stem cells (satellite cells) makes it possible to prevent and / or treat myopathies, more preferably DMD.
[0038] According to another embodiment, the pharmacological and / or genetic activators of the TSHR signaling pathway in muscle stem cells (satellite cells) used according to the invention make it possible to prevent and / or treat sarcopenia.
[0039] Sarcopenia is a geriatric syndrome characterized initially by a decrease in muscular capacity due to age, which, as it worsens, will cause a deterioration in muscular strength and physical performance. Sarcopenia observed in the elderly is attributable to the aging process but can be accelerated by pathological and behavioral factors such as malnutrition and a sedentary lifestyle. From the age of 30, muscle degeneration of 3 to 8% per decade is observed. Muscle tissue is replaced by fat mass and this loss accelerates from the age of 50. Indeed, muscle mass declines by approximately 1 to 2% per year after the age of 50, while strength declines by an average of 1.5% per year between the ages of 50 and 60 (-15%), then at a rate of 3%. per year, or a loss of 30% per decade after age 60.
[0040] According to a preferred embodiment of the invention, the activator of the TSHR signaling pathway in muscle stem cells (satellite cells) used according to the invention is an activator chosen from a TSHR receptor agonist or an adenylate cyclase activator, taken alone or in combination.
[0041] By TSHR receptor agonist used according to the invention is meant a compound capable of activating the TSHR receptor directly by binding to the TSHR receptor or indirectly via other compound(s).
[0042] Examples of TSHR receptor agonists include recombinant human TSH (rhTSH) Thyrogen®, a TSHR-stimulating antibody (such as M22), NCGC00161870 known as C2 and consisting of the E1 and E2 enantiomers, NCGC00379308, and MSql.
[0043] L’activateur pharmacologique utilisé selon l’invention est préférentiellement un activateur de l’adénylate cyclase choisi parmi NKH 477 (6-[3-(dimethylamino) propionyl] forskolin), cw008, DMAPD (6- [3-(dimethylamino)propionyl] -14,15-dihydro-forskolin), PACAP-27, PACAP-3 8, Glucagone, Isoproterenol, Octopamine, PACAP 27 Amine, Prostaglandine D2 / E1 / E2 / I2, Vasopressina, Forskoline et ses analogues comme 6-Acetyl-7-deacetyl-Forskoline, 7-Deacetyl-7-O-4hemisuccinyl-Forskoline, 7-Deacetyl-7-(O-N- methylpiperazino)-y-butryl-Dihydrochlonde-Forskoline, 7-deacetyl-forskoline (D3533), 6-[3-(dimethylamino)propionyl]forskoline, 6-[N-(2-isothiocyanatoethyl)aminocarbonyl]forskoline, 5,6-dehydroxy-7-deacetyl-7-nicotinoylforskoline, 6-acetyl-7-deacetyl-forskoline, 7-deacetyl-7-O-hemisuccinyl-forskoline, 1,9-dideoxy-forskolin (D3658), préférentiellement la Forskoline.
[0044] According to another preferred embodiment of the invention, the activator of the TSHR signaling pathway in muscle stem cells (satellite cells) used according to the invention is a genetic activator.
[0045] Preferably, the genetic activator used according to the invention consists of a vector chosen from a liposome comprising a protein sequence of the thyroid-stimulating hormone receptor (TSHR) of SEQ ID NO: or a functional variant having a protein sequence at least 60% identical to the sequence SEQ ID NO: 1, an adenoviral vector comprising the protein sequence of SEQ ID NO: 1 or a functional variant having a protein sequence at least 60% identical to the sequence SEQ ID NO: 1, or a nucleotide sequence of the TSHR of SEQ ID NO: 2 or a functional variant having a nucleotide sequence at least 60% identical to the sequence SEQ ID NO: 2, and an adenoviral vector comprising a CRISPR-Cas9 sequence fused with a transactivator domain preferentially chosen from VP 16, VP64, p65, NC01A1, FOXO1A to activate TSHR expression.
[0046] Nucleotide means any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Polynucleotides include, but are not limited to, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single- and triple-stranded regions, single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded regions, or a mixture of single- and double-stranded regions. As used herein, the term "polynucleotide(s)" also includes the DNAs or RNAs described above that contain one or more modified bases. Thus, DNA or RNA whose backbones are modified for stability or other reasons are "polynucleotides" as that term is used here.In addition, DNA or RNA comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as that term is used herein. It will be appreciated that a wide variety of modifications have been made to DNA and RNA, which serve many useful purposes known to those skilled in the art. The term "polynucleotide(s)" as used herein encompasses such chemically, enzymatically, or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including, for example, simple and complex cells. The term "polynucleotide(s)" also encompasses short polynucleotides often referred to as oligonucleotides.
[0047] A protein sequence means any peptide or protein comprising two or more amino acids linked together by peptide bonds or modified peptide bonds. The term "polypeptide(s)" refers to both short chains, commonly referred to as peptides, oligopeptides and oligomers, and longer chains generally referred to as proteins. Polypeptides may contain amino acids other than the 20 amino acids encoded by the gene. "Polypeptides" include those that are modified by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques. Such modifications are well described in the scientific literature and are well known to those skilled in the art. It will be appreciated that the same type of modification may be present to the same or different degrees at multiple sites in a given polypeptide.Similarly, a given polypeptide can contain many types of modification. Modification can occur anywhere in a polypeptide, including the peptide backbone, amino acid side chains, and amino or carboxylic termini. The . modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, crosslinking, cyclization, disulfide bond formation, demethylation, covalent crosslink formation, cysteine formation, pyroglutamate formation, formylation, gamma-carboxylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, attachment to lipids, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, selenoylation, sulfation, addition of amino acids to proteins via transfer RNA,such as arginylation, and ubiquitination. Polypeptides can be branched or cyclic, with or without branching. Cyclic, branched, and unbranched polypeptides can result from natural post-translational processes and can also be manufactured by entirely synthetic methods.
[0048] Preferably, the protein acid sequence of TSHR is at least 60% identical to the sequence SEQ ID NO: 1, for example 65%, 70%, 75%, 80%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, more preferably at least 95% identical to the sequence SEQ ID NO: 1, for example 96%, 97%, 98%, 99%, even more preferably is identical to the sequence SEQ ID NO: 1.
[0049] Preferably, the nucleic acid sequence of TSHR is at least 60% identical to the sequence SEQ ID NO: 2, for example 65%, 70%, 75%, 80%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, more preferably at least 95% identical to the sequence SEQ ID NO: 2, for example 96%, 97%, 98%, 99%, even more preferably is identical to the sequence SEQ ID NO: 2.
[0050] By identity is meant a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparison of the sequences. In the art, "identity" also means the degree of sequence relatedness between the polypeptide or polynucleotide sequences, as the case may be, as determined by the correspondence between the strings of those sequences. “Identity” and “similarity” can be readily calculated by known methods, including, but not limited to, those described in the following references (Computational Molecular Biology, Lesk AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and genome Projects, Smith DW, ed., Academie Press, New York. 1993; Computer Analysis of sequence Data, Part I, Griffin AM, and Griffin HG, eds., Humana Press. New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje G., Academie Press, 1987; and sequence Analysis Primer, Gribskov M. and Devereux J., eds., M Stockton Press, New York, 1991; and Carillo H., and Lipman D., SIAM J. Applied Math., 48:1073 (1998)). Identity determination methods are designed to give the highest match between the sequences tested. In addition, identity determination methods are codified in publicly available computer programs. Computer program methods for determining the identity between two sequences include, but are not limited to, the GCG package (Devereux J. et al., Nucleic Acids Research 12(1):387 (1984)), BLASTP, BLASTN, and FASTA (Altschul SF et al., J. Molec. Biol. 215:403-410 (1990)). The BLAST X program is 12 publicly available from NCBI and other sources (BLAST Manual, Altschul S. et al., NCBI NLM NUH Bethesda, MD 20894; Altschul S. et al., J. Mol Biol. 215: 403-410 (1990)).
[0051] A variant means a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. The nucleotide changes may result in substitutions, additions, deletions, fusions, and / or truncations of amino acids in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another reference polypeptide.
[0052] Generally, the differences are limited such that the sequences of the reference polypeptide and the variant are generally very similar and, in many regions, identical. A variant polypeptide and a reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, and / or deletions in any combination. A substituted or inserted amino acid residue may or may not be a residue encoded by the genetic code.
[0053] The present invention also includes variants of each of the polypeptides of the invention, i.e., polypeptides that vary from the references by conservative amino acid substitutions, whereby one residue is replaced by another having similar characteristics. Typical conservative amino acid substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues, Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or the aromatic residues Phe and Tyr. Such conservative mutations include mutations that exchange one amino acid for another in one of the following groups: 1. Small aliphatic residues, non-polar or slightly polar: Ala, Ser, Thr, Pro and Gly; 2. Polar, negatively charged residues and their amides: Asp, Asn, Glu and Gln; 3. Polar, positively charged residues: His, Arg and Lys; 4. Large, non-polar aliphatic residues: Met, Leu, Ile, Val and Cys; and 5. Aromatic residues: Phe, Tyr and Trp.
[0054] These conservative variations may further include the following: Original Residues Variations Ala Gly, Ser Arg Lys Asn Gin, His Asp Glu Cys Ser Gin Asn Glu Asp Gly Ala, Pro His Asn, Gin Ile Leu, Val Leu Ile, Val Lys Arg, Gin, Glu Met Leu, Tyr, Ile Phe Met, Leu, Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp, Phe Val Ile, Leu
[0055] Preferably, variants in which several, for example 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted or added in any combination. A variant of a polynucleotide or polypeptide may be of natural origin, such as an allelic variant, or it may be a variant that is not known to be of natural origin. Non-natural variants of polynucleotides and polypeptides may be obtained by mutagenesis techniques, by direct synthesis and by other recombination methods known to those skilled in the art.
[0056] As mentioned above, in addition to GC content and / or ARF number, sequence optimization may also include decreasing the number of CpG islands in the sequence and / or decreasing the number of splice donor and acceptor sites.
[0057] Of course, as is well known to those skilled in the art, sequence optimization is a balance between all of these parameters, meaning that a sequence can be considered optimized if at least one of the above parameters is improved while one or more of the other parameters are not, as long as the optimized sequence leads to an improvement of the transgene, such as an improvement in expression and / or a decrease in the immune response to the transgene in vivo.
[0058] Preferably, the transgene of interest codes for a human TSHR, and the nucleic acid sequence coding for the human TSHR protein comprises an optimized sequence identical to the sequence SEQ ID NO: 2.
[0059] Liposome is understood to mean an artificial vesicle formed by concentric lipid bilayers, trapping aqueous compartments between them. They are obtained from a wide variety of amphiphilic lipids, most often phospholipids. When such compounds are placed in the presence of an excess of aqueous solution, they organize themselves in such a way as to minimize the interactions between their hydrocarbon chains and water.
[0060] The genetic activator preferentially used according to the invention is an adenoviral vector, more preferentially an adeno-associated virus (AAV), even more preferentially an AAV8 or an AAV9.
[0061] Another subject of the invention relates to a combination of a pharmacological activator of the TSHR signaling pathway in muscle stem cells (satellite cells) and a genetic activator of the TSHR signaling pathway in muscle stem cells (satellite cells) for its use in preserving and regenerating muscle structure and function by blocking senescence, preferably for preventing and / or treating myopathies, more preferably DMD or for preventing and / or treating sarcopenia.
[0062] According to a particularly preferred embodiment of the invention, in the combination used according to the invention, the pharmacological activator is Forskolin and the genetic activator is an adeno-associated virus (AAV) comprising a protein sequence of the thyroid-stimulating hormone receptor (TSHR) of SEQ ID NO: 1 or a functional variant having a protein sequence at least 60% identical to the sequence SEQ ID NO: 1, or a nucleotide sequence of the TSHR of SEQ ID NO: 2 or a functional variant having a nucleotide sequence at least 60% identical to the sequence SEQ ID NO: 2, more preferably an AAV8 or an AAV9.
[0063] Another subject of the invention relates to an adenoviral vector comprising a protein sequence of the thyroid-stimulating hormone receptor (TSHR) of SEQ ID NO: 1 or a functional variant having a protein sequence at least 60% identical to the sequence SEQ ID NO: 1, or a nucleotide sequence of the TSHR of SEQ ID NO: 2 or a functional variant having a nucleotide sequence at least 60% identical to the sequence SEQ ID NO: 2 for its use as a medicament.
[0064] The adenoviral vector preferentially used according to the invention is an adeno-associated virus (AAV), preferentially an AAV8 or an AAV9.
[0065] The adenoviral vector is preferentially used according to the invention to preserve and regenerate muscle structure and function by blocking senescence, more preferentially to prevent and / or treat myopathies, even more preferentially DMD.
[0066] According to another embodiment of the invention, the adenoviral vector is preferentially used according to the invention to prevent and / or treat sarcopenia. Examples
[0067] Data analysis was performed using GraphPad Prism software, version 6.0. Data are expressed as mean ± standard deviation. Example 1:
[0068] Generation of R-DMDdel52 rats:
[0069] The R-DMDdel52 rat model is generated by the deletion of 188 bp (base pairs) and the generation of a premature stop codon at exon 52 of the Dys-trophin (DMD) gene to produce a loss of function of the allele responsible for dystrophin production.
[0070] The rat exon 52 sequence (ENSRNOE00000518152) and the surrounding intronic sequences were selected to identify guide RNA sequences (sgRNAs) by the BWA algorithm for genome editing by the CRISPR method.
[0071] After in vitro validation, two 3' and 5' sgRNAs were selected and mid-injected into the oocytes of Sprague Dawley rats.
[0072] F0 animals were screened by junction PCR genotyping. Genotyping is performed on DNA extracted from tail or ear biopsies.
[0073] The PCR mix was prepared with Dream Taq 10X buffer (ThermoFisher Scientific, Cat#B65), 0.25mM dNTP (10mM), 0.3pM forward primer (5'-CTAACGCATTTAAAATATGCTGTCA-3'), 0.3 pM reverse primer (5'-GTTGGCTTAGCTCAACAACCAAGAT-3', 100pM), 0.03U / pl DreamTaq and approximately 150ng of DNA. PCR was performed using the Thermal Cycler 2720 with the following thermal program: initial denaturation at 95°C for 5 minutes, 40 cycles of denaturation at 95°C for 10 seconds, primer annealing at 60°C for 30 seconds and elongation at 72°C for 45 seconds, and the final elongation at 72°C for 5 minutes.
[0074] The deletion of exon 52 was detected on a 2% agarose gel.
[0075] The rats were housed in a pathogen-free facility with 12-hour light and 12-hour dark cycles, in accordance with European Directive 2010 / 63 / EU.
[0076] Only male rats were used for the experiments because the mutation is carried on the X chromosome.
[0077] The animals were handled in accordance with national and European guidelines, and the protocols were approved by the ethics committee of the French Ministry (APAFIS#25606- 202005311746599).
[0078] Dystrophin expression was then assessed by immunofluorescence (Figure 1A) and western blot (Figure 1B) in the muscle of WT and R-DMDdel52 rats.
[0079] Western blotting was performed by cryosections of frozen muscles that were homogenized using a dounce homogenizer in a lysis buffer containing 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.5% NP40 and a cocktail of Hait protease inhibitors (Pierce).
[0080] Samples were then centrifuged for 5 minutes at 1500g and denatured at room temperature for 30 minutes with Laemmli buffer. Protein concentration was determined by the Bradford assay (Pierce). Proteins were separated by electrophoresis (Nu-PAGE 4-12% Bis-Tris gel; Life Technologies) then transferred to nitrocellulose membranes (GE Healthcare) and labeled with primary antibodies and horseradish peroxidase-coupled secondary antibodies. The primary antibody used is Dystrophin (DYS2, Leica) and Talpha-tubulin (Sigma, T5168). Signals were visualized with SuperSignal West Pico chemiluminescent substrate (Pierce). Images were acquired with Chemidoc MP (Biorad).
[0081] This determined that dystrophin is not expressed in R-DMDdel52 rats compared to WT rats. (Figure 1A-B).
[0082] A survival curve was established to compare the survival probability between WT and R-DMDdel52 rats as a function of the number of days. This showed that R-DMDdel52 rats die after 14 months of life, unlike WT rats.
[0083] Furthermore, R-DMDdel52 rats exhibit significantly lower body mass than WT controls from 3 months of age, with a sharp decrease in body mass index and body length at 12 months of age (Table 1).
[0084] Consistent with the progressive loss of muscle mass, a reduction in the weight of the Tibialis anterior (TA) and soleus was observed in 12-month-old R-DMDdel52 rats compared to WT rats.
[0085] Histological examination was performed by hematoxylin and eosin (H&E) and staining Sirius red at the anterior tibia in R-DMDdel52 rats compared with WT rats. (FiglD-G)
[0086] For hematoxylin and eosin staining, TA muscles were isolated from 12-month-old WT and R-DMDdel52 rats. After isolation, muscles were immediately frozen in liquid nitrogen-cooled isopentane and sectioned at 7 pm.
[0087] The slides are immersed in Mayer's hematoxylin (Sigma-Aldrich) for 3 minutes and after rinsing in deionized water, they are immersed in a lithium carbonate solution for 3 seconds, then incubated in eosin for 30 seconds. After washing in distilled water, the slides are immersed in 50% and 70% ethanol, then equilibrated in 95% and 100% ethanol.
[0088] The slides were mounted with Eurokit after being soaked in xylene.
[0089] For Sirius Red staining, slides are thawed for 20 minutes at room temperature (RT) and immersed in 90% EtOH for 2 minutes before staining begins, incubating the samples for 25 minutes in picrosirius red solution (Sigma-Aldrich). Slides are then washed extensively with water and dehydrated in 100% ethanol.
[0090] After clarification with xylene, the slides were mounted in Eurokit.
[0091] This made it possible to demonstrate that the muscles of R-DMDdel52 rats exhibit signs of severe DMD pathology with the presence of endomysial fibrosis, altered fiber morphology, and inflammatory cell invasion. (Fig. D, upper panels).
[0092] Indeed, severe fibrotic deposition is confirmed by Sirius red staining. (FiglD, lower panels). The extent of fibrosis is quantified by measuring the percentage of the area occupied by connective tissue, showing statistically significant differences between WT and R-DMDdel52 rats at the anterior tibia (Fig. 1E). Indeed, R-DMDdel52 rats exhibit approximately 2.5 times more fibrosis than WT rats.
[0093] The presence of central nuclei is also evaluated, as a pathological marker of a muscle undergoing a degeneration / regeneration event. The R-DMDdel52 muscle exhibited a considerable number of central nucleus fibers compared to controls. (Fig.lF)
[0094] Finally, the presence of atrophic fibers is confirmed, with a reduced cross-sectional area of muscle fibers, which contribute to muscle wasting (Shin, Jonghyun et al. “Wasting mechanisms in muscular dystrophy" The international journal of biochemistry & cell biology vol. 45,10 (2013): 2266-79. doi: 10.1016 / j.biocel.2013.05.001). (FiglG)
[0095] The extraocular muscles (EOM) were also analyzed, as they are selective tively spared in Duchenne muscular dystrophy (Kaminski, HJ et al. “Extraocular muscles are spared in advanced Duchenne dystrophy” Annals of neurology vol. 32,4 (1992): 586-8. doi: 10.1002 / ana.4103204181992). EOMs are complex striated muscles that exhibit distinct biochemical, mechanical, and physiological properties compared to their limb counterparts (Bondi, AY, and DJ Chiarandini. “Morphology and electrophysiologic identification ofmultiply innervated fibers in rat extraocular muscles.” Investigative ophthalmology & visual science vol. 24,4 (1983): 516-9., Jacoby et al., 1990, Kono et al., 2005, Fraterman et al., 2007). Hematoxylin / eosin and Sirius Red stainings confirmed the preservation of MEOs isolated from 12-month-old R-DMDdel52 animals (Fig. HK), with no evidence of significant inflammation or fibrosis compared to controls (Fig. 1H-I).
[0096] Interestingly, R-DMDdel52 MEOs exhibited a high number of central core myofibers compared to WT muscles (Fig. 1J), but to a lesser extent compared to TAs (Fig. 1F). Furthermore, fiber size analysis did not show significant variation between MEOs from 12-month-old WT and R-DMDdel52 rats (Fig. 1K).
[0097] These results show that R-DMDdel52 exhibits a progressive and severe muscular dystrophy characterized by well-described features of DMD pathophysiology, including the fact that extraocular muscles are specifically not affected by the disease.
[0098] Table 1: Parameter 3 weeks 6 months 12 months WT DM0 WT DMD WT DMD Body mass (g) 96.9 ± 21.4 76.0 ± 0.4 621.3 ± 38.4 547.2 ± 60.0* 731.1 ±63.3 337.7 ±88.9"" Indexed by Body Mass (e fg / ern») 0.39 + 0.03 0.34 * 0.03 0.70 + 0.06 0.63 + 0.04 0.74 + 0.04 0.34 + 0.22 “ Body height (cm) 15.7 ±1.2 14.9 ±0.6 29.1 + 1.0 29.0+1.3 30.5 ± 1.1 29.6 ± 0.7 Tsbialis anterior (g; 0.18 * 0.03 0.12 + 0.01 1.21 * 0.34 0.97 + 0.22 1.15 + 0.05 0.55 + 0.21 " Heart (g) 0.47 + 0.06 0.47 ± 0.05 1.77 ±0.10 1.84 + 0.48 1.86 + 0.11 2.20 + 0.45 § Soleus (g) 0.054 + 0.03 0.038 + 0.02 0.39 + 0.03 0.25 + 0.13 0.35 ±0.10 0.15 ± 0.08 * The p values are calculated with reference to the WT ' p<0.05 ""pcO.OOl § p-«0.07 Example 2:
[0099] Extraocular muscles do not exhibit progressive muscle regeneration defects in the rat DMD model.
[0100] Muscle tissue damage leads to necrosis of muscle fibers which triggers muscle regeneration by activating the muscle satellite cell pool. quiescent cells located near muscle fibers.
[0101] The time course of muscle regeneration in the anterior tibia of R-DMDdel52 rats was assessed using immunofluorescence for embryonic myosin heavy chain (eMHC), a specific marker of developing and regenerating myofibers on histological sections of skeletal muscles.
[0102] Immunohistochemistry was thus carried out on cryosections: Fresh frozen muscles were sectioned with the Leica CM3050S cryostat (Leica Biosystems) at 7 pm thickness on Super Frost Plus slides (Thermo scientific, 10149870) and stored at -80°C.
[0103] Slides were thawed for approximately 20 minutes at room temperature, rehydrated for 5 minutes in 1X PBS, and then fixed with 4% PFA in 1X PBS for 10 minutes at 4°C. After washes in 1X PBS, slides were placed in cold acetone and methanol (1:1) for 6 minutes at -20°C, then incubated with 10% BSA for 1 hour of blocking. Primary antibodies were added to 1% BSA and incubated overnight (O / N) at 4°C.
[0104] The following primary antibodies were used: Pax7 (Santa Cruz Biotechnology, sc-81648), ki67 (Abcam, sp6 abl6667), Cdkn2a (Abcam Anti-CDKN2A / pl6INK4a, Abl08349), Cdknla (Thermofisher, bs-10129R) and yH2AX (Abcam, abl1174). After repeated washing, the slides were incubated with Alexa fluor secondary antibodies for 45 minutes at room temperature. Laminin staining was performed after incubation of the secondary antibodies, for 1 h at 37°C using a conjugated antibody (NB300-144AF647).
[0105] Nuclei were stained with Hoechst (Sigma-Aldrich, B2261). Fluorescence was analyzed with an LSM800 confocal apparatus. Immunostaining of embryonic myosin heavy chain (eMHC), dystrophin, and [3-dystroglycan] was performed without fixation and with permeabilization in 0.5% Triton in 1X PBS for 5 minutes. eMHC (sc-53091), dystrophin (Leica, DYS2-CE), [3-dystroglycan (Leica, B-DG-CE), and laminin (Sigma-Aldrich, L9393) were incubated in open air.
[0106] Incubation of secondary antibodies and staining of nuclei were performed as described above. Fluorescence was analyzed with an LSM800 confocal apparatus.
[0107] A large number of eMHC-positive myofibers in the TAs of 3-week-old R-DMDdel52 rats is observed, whereas they were completely absent in WT muscles (Fig. 2A).
[0108] A sharp decrease in the number of regenerating fibers was observed over time (Fig. 2A-B), indicating a progressive reduction in muscle regeneration. during the progression of muscular dystrophy.
[0109] In contrast, although it is slightly increased in R-DMDdel52 rats compared to WT rats, the regeneration process is stable and limited during pathological progression in the extraocular muscles.
[0110] These data suggest that MEOs exhibit increased regenerative performance compared to other muscles.
[0111] Since the regenerative capacity of skeletal muscles is linked to satellite cells, we decided to evaluate the number and myogenic status of MSCs in vivo.
[0112] Co-immunostaining is performed for Pax7 and Ki67, a proliferation and activation marker, on histological sections of skeletal muscles isolated from the TA and MEO of WT and R-DMDdel52 rats.
[0113] As shown in Figures 2E and 2H, no difference is observed in the number of MSCs per fiber between WT and R-DMDdel52 TA or MEO muscles (quantified in Figures 2F and 2I), indicating that MSCs are not lost during the pathological progression of DMD.
[0114] The cell cycle status of MSCs is then evaluated in WT and R-DMDdel52 rats. It can be said that in the TA muscle of WT and R-DMDdel52 rats, MSCs divide only at early stages (3 weeks), while remaining arrested in their cell cycle at later stages of the pathology, including in the pathological context of DMD.
[0115] In contrast, a large proportion of MSCs analyzed on histological sections of MEO expressed the proliferation marker, Ki67, both in WT and R-DMDdel52 samples and at all stages examined, including in WT and dystrophic rats aged 12 months (Fig.2H-J).
[0116] This suggests that MEO MSCs are highly active in a WT context and retain their regenerative capacity in R-DMDdel52 animals. Example 3:
[0117] R-DMDdel52 TA MSCs exhibit altered myogenic potential in vitro:
[0118] To further investigate the properties of WT and R-DMDdel52 MSCs, satellite cells from the Tibialis Anterior and extraocular muscles were isolated and their proliferative capacity assessed in culture.
[0119] For this, cells were fixed with 4% PFA for 10 minutes at 4°C and permeabilized with 0.5% Triton in 1X PBS for 6 minutes. After blocking with 10% BSA for 30 minutes at room temperature, cells were incubated O / N at 4°C with the following primary antibodies: Pax7 (Santa Cruz Bio-technology, sc-81648), MyoD (Dako, clone 5.8A, M3512), ki67 (Abcam, sp6 abl6667), sarcomeric myosin heavy chain (MF20, DSHB, AB_2147781).
[0120] Significant differences were not observed in the proliferative properties of MSCs isolated from the TA or MEO of 3-week-old WT and R-DMDdel52 rats (Fig.3A-C).
[0121] Furthermore, cultures of myoblasts derived from WT and R-DMDdel52 MSCs isolated from TA and MEO muscle controls did not show significant differences in myogenic differentiation (Fig.3D-G).
[0122] It can be seen that MSCs derived from TA of 6-month-old R-DMDdel52 rats exhibit a decrease in the percentage of MyoD-positive myoblasts co-expressing Ki67 compared to WT control cells (Fig. 3I-J).
[0123] However, there is no significant proliferation difference in myoblasts isolated from 6-month-old R-DMDdel52 MEOs compared to WT MEOs, suggesting that R-DMDdel52 extraocular muscle MSCs retain their proliferative capacity ex vivo (Fig. 31-J).
[0124] Next, myogenic differentiation was assessed on cultured cells isolated from TA muscles of WT and R-DMDdel52 rats at 6 months of age.
[0125] While the differentiation of myogenic cell cultures isolated from 6-month-old R-DMDdel52 MEOs was virtually indistinguishable from that of controls, a strong differentiation deficit was observed in R-DMDdel52 cell cultures isolated from TAs of the same rats. (Fig.3K-L)
[0126] Quantification showed a significant reduction in the fusion index as well as the number of nuclei per myotube per mm2 in cultured R-DMDdel52 TA cells compared to WT controls. (Fig. 3M-N)
[0127] Conversely, no significant differentiation defects were observed in myoblasts isolated from MEOs of 6-month-old dystrophic rats and WT rats. (Fig. 3M-N)
[0128] To assess whether the proliferation and differentiation defects observed when culturing cells isolated from R-DMDdel52 TA muscles are cell-autonomous, MSCs were purified from limb muscles by FACS sorting with CD45, CD31, Terll9 as exclusion markers and a7-integrin as a positive selection surface marker (Fig.S2A), allowing the culture of pure MSC-derived myoblasts ([Fig.3] OP).
[0129] FACS sorting is done by the following method: After cell dissociation, isolated hindlimb cells were incubated with CD45-PE-Cy7 (BD Pharmingen, 552848), Terll9-PE-Cy7 (BD Pharmingen, 557853), CD31-PE-Cy7 (BD Pharmingen, 561410), a7-integrin-FITC (CliniSciences, C179570-100) for 45 minutes at 4°C. After washing with HBSS supplemented with DNase (Sigma-Aldrich, DN25), cells are incubated with the vital dye 7-AAD (BD Pharmingen, 559925) and sorted with the BD FacsAria device. The MSC population has was identified as CD45:Terll9:CD31-negative and a7-integrin-positive.
[0130] A decrease in proliferative potential is observed in sorted R-DMDdel52 cells, as shown by the lower number of EdU-labeled (Pax7±:MyoD±) myoblasts (Fig. 3Q) in cultured cells from dystrophic limb muscles.
[0131] Sorted R-DMDdel52 muscle satellite cells also exhibit strong deficiencies in myogenic differentiation with the formation of small myotubes with fewer nuclei compared to WT cells (Fig. 3R-S).
[0132] Overall, these data demonstrate that proliferation and differentiation are impaired in MSCs isolated from R-DMDdel52 limb muscles, whereas MSCs from dystrophic MEOs retain their potential. Example 4:
[0133] Tibialis anterior R-DMDdel52 muscle satellite cells express senescence markers
[0134] In order to study the molecular and cellular changes occurring in the muscles of dystrophic rats, scRNA-seq was performed from TA muscles of 12-month-old R-DMDdel52 and WT rats.
[0135] Indeed, TA and extraocular muscle cells are extracted from 12-month-old WT and R-DMDdel52 rats and immediately digested with 3U / ml of Dispase II (Roche, 4942078001) and 0.5u / ml of Collagenase A (Roche, 10103586001) for 20 minutes in HBSS at 37°C with gentle agitation.
[0136] The cell suspension was passed through cell filters and centrifuged at 600g / minute for 5 minutes, at 4°C. The supernatant was removed and the cell pellet was resuspended in 20% fetal bovine serum (Cat#S 1810-500 Dominique Dutscher) in DMEM (Cat#41966-029 Gibco) supplemented with 25ng / ml bFGF (RP4037, Sigma-Aldrich) with 100 mg / ml penicillin / streptomycin (354234, Life Sciences) coated with matrigel (Sarstedt, #94.6140.802). The cells were grown for 48 hours to assess proliferation. After 48 h of proliferation, cells were cultured for 5 days in 5% fetal bovine serum to induce differentiation.
[0137] After dissociation, cells were filtered through 100 and 70qm cell strainers and sorted by FACS after incubation in DAPI (D9542, Sigma-Aldrich) to obtain a clean cell suspension removing dead cells and debris.
[0138] The snRNA-seq was performed using the Chromium Next GEM Single Cell 3'Gcnc Expression V3 kit (10X Genomics) following the manufacturing protocol. Sequencing was performed on the Illumina NexSeq 550 system with the High Output Kit v2.5 (75 cycles, Illumina 20024906).
[0139] Cells were filtered based on readings per sample, content Mitochondrial and ribosomal RNA and predicted doublets to obtain an average of 6247 cells per sample (Table 2). Cell identity was assessed based on the expression of well-established markers and the data were visualized by T-distributed stochastic neighborhood embedding (Jamieson, Andrew R et al. “Exploring nonlinear feature space dimension reduction and data representation in breast Cadx with Laplacian eigenmaps and t-SNE” Medical physics vol. 37,1 (2010): 339-51. doi: 10.1118 / 1.3267037) (t-SNE; Fig. 4A). A total of 9 major muscle-resident cell groups are identified. (Fig.S2A).
[0140] WT and R-DMDdel52 cells are marked on the t-SNE map, highlighting disease-related changes at the transcriptomic level (Fig. 4B). These changes were evident for MSCs that exhibited distinct gene expression signatures between WT and R-DMDdel52 samples (Fig. 4C).
[0141] The identification of genes differentially expressed in the group of MSCs is thus studied.
[0142] The specific induction of two growth arrest and senescence markers in R-DMDdel52 MSCs compared to controls is identified: the cyclin-dependent kinase inhibitors Cdkn1a (p21) and Cdkn2a (pl6Ink4a,Cdkn2a ) (Hernandez-Segura, Alejandra et al. ^Hallmarks of Cellular Senescence.” Trends in cell biology vol. 28,6 (2018): 436-453. doi:10.1016 / j.tcb.2018.02.001) (Fig. 4C-D).
[0143] Expression of Cdkn1a and Cdkn2a is observed in MSCs at the protein level by co-immunostaining with Pax7 on muscle sections isolated from 6-month-old R-DMDdel52 and WT rats.
[0144] The presence of the phosphorylated form of histone H2A gamma X (yH2AX), a marker of DNA damage induced in senescent cells (Wang, Zhong et al. "RNA-Seq: a revolutionary tool for transcriptomics.” Nature reviews. Genetics vol. 10,1 (2009): 57-63. doi:10.1038 / nrg2484; Bemadotte, Alexandra et al. "Markers of cellular senescence. Telomere shortening as a marker of cellular senescence.” Aging vol. 8,1 (2016): 3-11. doi: 10.18632 / aging. 100871 ; Dungan, Cory M et al. “In vivo analysis ofyH2AX+ cells in skeletal muscle from aged and obese humans.” FASEB journal: official publication of the Federation of American Societies for Experimental Biology vol. 34.5 (2020): 7018-7035. doi: 10.1096 / fj.202000111RR) in MSCs from dystrophic rats compared to WT (Fig. 4F-H) is also observed.
[0145] Strikingly, the senescence signature of MSCs in vivo (Cdkn2a, Cdkn1a, yH2AX) was associated with disease progression in R-DMDdel52 (Fig. 4H-J).
[0146] These data suggest that TA R-DMDdel52 MSCs progressively acquire a senescence signature during disease progression, which is consistent with the progressive reduction in regenerative potential and phenotypes observed in ex vivo cultures of CSM.
[0147] Table 2: Lshmatâm of the number of -cells Lectum tnrçtWM» by ceJiule Median cones by ccllde Number of JedWM (kMleÿ-valid bars Saturation dn seqwen<;age 3 53« 'V.k'i 473 307 1 ■ ■ K 92. / ¾ Wvlb Va 56 / 05 507 1 '0 78'3 97.1% 86.5¾ 1 W1 MEO 1 W .l6a t 0.12 449 Ut 98.3% DMb MEO 3MA Î44443 f 350 446 / 62 ' / Jl 977 % Example 5:
[0148] MSCs from human patients with DMP express senescence markers
[0149] To assess whether muscle stem cell senescence in dystrophic rats replicates human DMD pathology, the regenerative potential and presence of a senescence signature of MSCs on human deltoid biopsies from DMD patients and control patients are evaluated.
[0150] DMD muscle biopsies, divided by age groups (1-2, 3-4, 5-6, 7-8 years), and control biopsies are stained for embryonic myosin heavy chain (eMHC) to label regenerating myofibers (Fig. 5A).
[0151] Quantification of eMHC-positive myofibers showed a progressive reduction in the regenerative capacities of DMD muscles, with marked differences between early-stage (1-2 years) and 7-8 years samples (Fig. 5B).
[0152] Co-immunostaining of Pax7 with Cdkn2a and yH2AX is performed on histological sections from DMD biopsies and control biopsies in order to assess the senescence status of human muscle satellite cells.
[0153] Muscle sections from DMD patients exhibited substantial numbers of Pax7-positive MSCs that co-expressed Cdkn2a (Fig.5C-E) and yH2AX (Fig.5F-H) compared to control biopsies that barely expressed Cdkn2a and exhibited low levels of yH2AX (Fig.5C-H).
[0154] Furthermore, the number of DMD MSCs expressing Cdkn2a increases with age (r=0.84, Pearson correlation, Fig.7E), without revealing a strong positive correlation between DMD MSCs expressing yH2AX and disease progression (r=-0.34, Pearson correlation, Fig.7H).
[0155] To conclude, human DMD MSCs express an early and progressive senescent signature, associated with a gradual decline in muscle regeneration potential. Example 6:
[0156] Rat MSCs express a MEO-specific signature distinct from that of TAs
[0157] MEOs are collected from 12-month-old WT and R-DMDdel52 rats and the cells are isolated and analyzed by scRNAseq with the lOx Genomics platform in order to to identify specific characteristics of MEOs associated with effective regenerative potential in DMD.
[0158] The same protocol as for the TA samples is used to characterize the MEO samples, identifying an average of 2505 cells.
[0159] The transcriptomic profile of TA and MEO MSCs from WT and R-DMDdel52 animals is compared and the specific expression of the Pitx2 gene is detected (Evano, Brendan et al. “Dynamics ofAsymmetric and Symmetric Divisions of Muscle Stem Cells In Vivo and on Artificial Niches.” Cell reports vol. 30,10 (2020): 3195-3206.e7. doi:10.1016 / j.celrep.2020.01.097; Noden, Drew M, and Philippa Francis-West. “The differentiation and morphogenesis of craniofacial muscles.” Developmental dynamics : an official publication of the American Association of Anatomists vol. 235,5 (2006): 1194-218. doi: 10.1002 / dvdy.20697) in the CSM from WT and R-DMDdel52 MEO, confirming the specific identity of these cells (Fig. 6A-C).
[0160] As expected, MSCs isolated from MEOs did not exhibit a senescence signature, with Cdkn1a and Cdkn2a being selectively expressed only in MSCs from the R-DMDdel52 TA (Fig. 6B).
[0161] The absence of Cdkn1a and Cdkn2a transcripts is also validated as well as the specific expression of TSHR on muscle satellite cells freshly isolated from MEO by qRT-PCR (Fig. 6D): RNA is extracted using the RNAqueous-Micro total RNA isolation kit (Invitrogen) and reverse transcribed using Su-perScript™ III reverse transcriptase (Invitrogen, 18080093) according to the manufacturer's instructions.
[0162] qPCR is performed using the StepOnePlus Real-Time PCR System (Applied Biosystems) and SYBR Green Detection Tools (Applied Biosystems).
[0163] Results are reported as relative gene expression (2-DDCT) using vehicle-treated cells or extraocular-derived myoblasts as reference. Gene expression is normalized to [3-actin] expression levels.
[0164] Co-immunostainings for Pax7 and senescence markers are also performed: Cdkn2a, Cdkn1a and yH2AX (Hernandez-Segura et al. 2018; Wang et al, 2009; Bernadotte et al, 2016; Dungan et al, 2020) (Fig.6E-G), showing the absence of their expression in Pax7-positive satellite cells of MEO.
[0165] Indeed, quantifications of the percentage of Pax7± / Cdkn2a ±1 Cdknla ±1 yH2AX± in the MEOs at 3 weeks, 6 and 12 months demonstrate that there are no differences between the WT and R-DMDdel52 samples.
[0166] These data confirm that MEO MSCs are protected from senescence and retain their myogenic potential in dystrophic rats. Example 7:
[0167] TSHR signaling regulates senescence in myoblasts isolated from MEOs of R-DMDdel52 rats.
[0168] TSHR, the thyroid-stimulating hormone receptor, is specifically expressed in MEO MSCs (Fig. 6A-C). The specific protein expression of TSHR in MEO MSCs is validated by TSHR immunofluorescence on freshly isolated myogenic cells from extraocular and limb muscles.
[0169] For TSHR staining, cells were permeabilized for 5 minutes with 0.1% Triton in 1X PBS, then incubated O / N with TSHR antibody (CliniSciences, BS-0003R). The following day, cells were washed in 1X PBS and incubated with Alexa fluor secondary antibodies for 45 minutes at room temperature. Finally, nuclei were counterstained with Hoechst (Sigma-Aldrich, B2261). Fluorescence was analyzed with an LSM800 confocal apparatus.
[0170] As shown in Figure 7A, TSHR is highly expressed in MEO-derived myoblasts at the cell membrane, whereas myoblasts isolated from limb muscles express low or undetectable level of TSHR.
[0171] To assess the functional significance of TSHR expression in MEO MSCs, myoblasts were isolated from WT MEO and treated with a selective TSH receptor antagonist, ML224 (Neumann et al., 2014).
[0172] For this, MSC-derived myoblasts were treated with 10pM of ML224 (HY12381-S, CliniSciences) for 2 days (proliferation) or 7 days (differentiation) or 20pM of Forskolin (F3917, Sigma-Amdrich) (following experiment) only for 48h. Control cells were treated with DMSO (D8418, Sigma Aldrich) as a vehicle for ML224 and Forskolin.
[0173] Proliferation was measured after 24 h of culture by adding a pulse of 10 mM 5-ethynyl-20-deoxyuridine (EdU) to the culture medium for 24 h (EdU Click-iT PLUS Kit C10640, Life Technologies).
[0174] Inhibition of TSHR signaling compromised myoblast proliferation with a significant decrease in Pax7± / MyoD± / EdU± cells compared to vehicle-treated cells (Fig. 7B-C).
[0175] This experiment is conducted under serum-free conditions to avoid any stimulation of TSHR by the presence of TSH in the serum, which explains the lower proliferative capacity of the myoblasts of the MEO treated with the vehicle, compared to the data presented previously (Fig. 31).
[0176] Furthermore, myoblasts from ML224-treated MEOs exhibited differentiation defects and compromised myotube formation associated with a significant reduction in fusion index compared to control cells treated with vehicle alone (Fig. 7D-E).
[0177] In addition, cultured MEO satellite cells treated with the TSHR inhibitor induced the expression of Cdkn1a (p21) and Cdkn2a (p16) (Fig. 7F), suggesting the acquisition of a senescence signature. Strikingly, ML224-treated MEO myoblasts exhibited a remarkably similar phenotype to cultured R-DMDdel52 limb myoblasts, reminiscent of senescent cells (Moustogiannis, Athanasios et al. “The Effects of Muscle CellAging on Myogenesis.” International journal of molecular sciences vol. 22,7 3721. 2 Apr. 2021, doi:10.3390 / ijms22073721).
[0178] These data demonstrate that TSHR signaling is necessary to prevent entry into senescence and maintain the myogenic potential of MSCs derived from dystrophic OME.
[0179] Next, it was hypothesized that TSHR signaling could also protect DMD MSC-derived myoblasts from entering senescence.
[0180] To validate this hypothesis, WT and R-DMDdel52 MSCs isolated from limb muscles were treated with Forskolin, a well-known activator of adenylate cyclase (Alasbahi & Melzing, 2012) and TSHR signaling.
[0181] Strikingly, forskolin-treated R-DMDdel52 myoblasts exhibited restored proliferation compared to control R-DMDdel52 cells, reaching the proliferative capacity of WT cells (Fig.7G-H).
[0182] Importantly, forskolin-exposed R-DMDdel52 myoblasts abolished the aberrant expression of Cdkn1a (p21) and Cdkn2a (p16), whereas vehicle-treated R-DMDdel52 myoblasts maintained the expression of these senescence markers (Fig. 51-J).
[0183] Finally, myoblasts from forskolin-treated R-DMDdel52 limbs exhibited enhanced differentiation potential compared to control R-DMDdel52 cells, forming significantly larger myotubes with a higher fusion index (Fig. 7K-L).
[0184] These data suggest that activation of AMP / PKA signaling can correct the proliferation and differentiation defects observed in R-DMDdel52 myoblasts.
Claims
Claims
1. A pharmacological and / or genetic activator of the thyroid-stimulating hormone receptor (TSHR) signaling pathway in muscle stem cells (satellite cells) for use in preserving and regenerating muscle structure and function by blocking senescence.
2. Activator for its use according to claim 1, for preventing and / or treating myopathies, preferably Duchenne muscular dystrophy (DMD).
3. Activator for use according to claim 1, for preventing and / or treating sarcopenia.
4. Pharmacological activator for its use according to one of claims 1 to 3, chosen from a TSHR receptor agonist or an adenylate cyclase activator.
5. Pharmacological activator for its use according to claim 4, characterized in that it is an activator of adenylate cyclase, preferably Forskolin.
6. Genetic activator for its use according to one of claims 1 to 3, characterized in that it consists of a vector chosen from a liposome comprising a protein sequence of the thyroid-stimulating hormone receptor (TSHR) of SEQ ID NO: 1 or a functional variant having a protein sequence at least 60% identical to the sequence SEQ ID NO: 1, an adenoviral vector comprising the protein sequence of SEQ ID NO: 1 or a functional variant having a protein sequence at least 60% identical to the sequence SEQ ID NO: 1, or a nucleotide sequence of the TSHR of SEQ ID NO: 2 or a functional variant having a nucleotide sequence at least 60% identical to the sequence SEQ ID NO: 2, and an adenoviral vector comprising a CRISPR-Cas9 sequence fused with a transactivator domain preferentially chosen from VP16, VP64, p65, NCO1A1, FOXO1A to activate TSHR expression.
7. Genetic activator for its use according to claim 6 or 7, characterized in that said adenoviral vector is an adeno-associated virus (AAV), preferably an AAV8 or an AAV9.
8. Combination of a pharmacological activator for use according to claim 4 or 5 and a genetic activator for use according to claim 6 or 7.
9. Combination for use according to claim 8, characterized in that the pharmacological activator is Forskolin and the genetic activator is an adeno-associated virus (AAV) comprising a protein sequence of the thyroid-stimulating hormone receptor (TSHR) of SEQ ID NO: 1 or a functional variant having a protein sequence at least 60% identical to the sequence SEQ ID NO: 1, or a nucleotide sequence of the TSHR of SEQ ID NO: 2 or a functional variant having a nucleotide sequence at least 60% identical to the sequence SEQ ID NO:
2.
10. Adenoviral vector characterized in that it comprises a protein sequence of the thyroid-stimulating hormone receptor (TSHR) of SEQ ID NO: 1 or a functional variant having a protein sequence at least 60% identical to the sequence SEQ ID NO: 1, or a nucleotide sequence of the TSHR of SEQ ID NO: 2 or a functional variant having a nucleotide sequence at least 60% identical to the sequence SEQ ID NO: 2 for use as a medicament.
11. Adenoviral vector for use according to claim 10, for preserving and regenerating muscle structure and function by blocking senescence.
12. Adenoviral vector for its use according to claim 11, for preventing and / or treating myopathies, preferably DMD.
13. Adenoviral vector for use according to claim 11, for preventing and / or treating sarcopenia.
14. Adenoviral vector for its use according to one of claims 10 to 13, characterized in that said vector is an adeno-associated virus (AAV), preferably an AAV8 or an AAV9.
